Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

Targeting Pediatric Vascular Stenoses using Pediatric HiPSC-derived Smooth Muscle Cells with N-Cadherin Mimetic Peptide Nanoparticle Drug Delivery

FY 2025-26

Summary
Supravalvular aortic stenosis (SVAS) is a rare congenital heart disease occurring in 1:20000 live births that entails narrowing of the aorta, the main artery providing blood from the heart. This vascular narrowing (stenosis) is driven by hyperproliferative vascular smooth muscle cells (SMCs). SVAS occurs in patients who have William's syndrome due to elastin gene deletions and in non-syndromic patients with elastin gene mutations. Children with SVAS can have heart failure and/or sudden cardiac death. Current treatments include surgery, catheter-based interventions and transplantations which are invasive and provide symptom relief. This is burdened by repeated restenosis (re-narrowing of blood vessels) requiring repeated interventions in young children.The cellular and molecular mechanisms that drive the stenoses in SVAS are poorly understood and represent an unmet need for targeted treatments. Our lab previously identified N-cadherin, a cell-cell adhesion molecule, as a critical mediator of SMC proliferation and migration in adult stenoses. We developed an N-cadherin mimetic peptide-complexed nanoparticle (PNP) system that stabilizes and restores the lost N-cadherin contacts on SMCs and thereby inhibits unregulated SMC migration found in stenoses. We propose that N-cadherin underlies the cellular dysregulation of SMCs in pediatric SVAS, and that our PNP system can be used to relieve restenosis in pediatric stenoses. Ultimately, this study will help identify new cellular mechanisms underlying SVAS and test a new nanoparticle drug delivery system. We are therefore proposing a new cell-specific therapeutic combined with nanomedicine to treat pediatric congenital heart disease.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559642
Name
Adil Aisha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Targeting Pediatric Vascular Stenoses using Pediatric HiPSC-derived Smooth Muscle Cells with N-Cadherin Mimetic Peptide Nanoparticle Drug Delivery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cardiovascular Matrix Biology; Congenital Heart Disease; Extracellular Matrices; Heart Failure; Human Induced Pluripotent Stem Cells; N-Cadherin; Nanoparticle Drug Delivery; Pediatric Stem Cell Application; Pediatric Vascular Stenoses; Smooth Muscle Cells
Abstract
Supravalvular aortic stenosis (SVAS) is a rare congenital heart disease occurring in 1:20000 live births that entails narrowing of the aorta, the main artery providing blood from the heart. This vascular narrowing (stenosis) is driven by hyperproliferative vascular smooth muscle cells (SMCs). SVAS occurs in patients who have William's syndrome due to elastin gene deletions and in non-syndromic patients with elastin gene mutations. Children with SVAS can have heart failure and/or sudden cardiac death. Current treatments include surgery, catheter-based interventions and transplantations which are invasive and provide symptom relief. This is burdened by repeated restenosis (re-narrowing of blood vessels) requiring repeated interventions in young children.The cellular and molecular mechanisms that drive the stenoses in SVAS are poorly understood and represent an unmet need for targeted treatments. Our lab previously identified N-cadherin, a cell-cell adhesion molecule, as a critical mediator of SMC proliferation and migration in adult stenoses. We developed an N-cadherin mimetic peptide-complexed nanoparticle (PNP) system that stabilizes and restores the lost N-cadherin contacts on SMCs and thereby inhibits unregulated SMC migration found in stenoses. We propose that N-cadherin underlies the cellular dysregulation of SMCs in pediatric SVAS, and that our PNP system can be used to relieve restenosis in pediatric stenoses. Ultimately, this study will help identify new cellular mechanisms underlying SVAS and test a new nanoparticle drug delivery system. We are therefore proposing a new cell-specific therapeutic combined with nanomedicine to treat pediatric congenital heart disease.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Adil, Aisha
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~